๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

โœ Scribed by Kwok-Hung Lai; Yang-Te Tsai; Shou-Dong Lee; Wai-Wah Ng; Ho-Chung Teng; Tseng-Nip Tam; Gin-Ho Lo; Han-Chieh Lin; Hwai-Jeng Lin; Jaw-Ching Wu; Chii-Shyan Lay; Sun-Sang Wang; Wing-Kai Chan

Publisher
Springer
Year
1989
Tongue
English
Weight
256 KB
Volume
23
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
โœ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti

A randomized multicenter phase II clinic
A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
โœ Qinghua Zhou; Xun Sun; Lingyuan Zeng; Jie Liu; Zhirong Zhang ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 151 KB

## From the clinical editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (dhad-pbca-nps) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls.